Skip to content

Corrections

Prices and policies in this market change constantly, and sometimes we simply get something wrong. When that happens, we fix it and say so here, newest first.

How we handle a mistake

When you or anyone else tells us something is wrong, we check it against the original source: the company’s own website for anything about a provider, and the study or FDA label for anything medical. If we were wrong, we fix the page and update its date.

Small fixes, like a typo or a broken link, are just fixed. Anything that changes what a reader would take away (a price, a disclosure, a safety fact, or something we said about a company) also gets an entry below, with the month it was made. We don’t quietly rewrite history: an entry stays here even after the page moves on.

Found something? Email ask@semawise.com with the page and the sentence. The rules we write to are in our editorial policy.

Corrections log

Prices mentioned below are what each company showed at the time of the correction. For today’s price, open the current review.

  1. Thyroid-cancer evidence and coffee advice corrected

    Our thyroid-cancer guide overstated what a study that found no statistically significant increase could establish. We removed an outdated “largest, most recent” claim, added a newer diabetes cohort, and explained the limits of drug-class evidence and short semaglutide follow-up. The MTC and MEN 2 prescribing restrictions remain. We also corrected blanket reassurance and unsupported explanations in the coffee guide, including its figures and FAQs. It now distinguishes tablet timing, individual caffeine tolerance, and fluid loss during illness.

  2. Fatigue and hair loss: the labeling needed a clearer account

    Our fatigue guide understated tiredness as a reported Wegovy side effect and gave recovery timelines the evidence did not establish. Our hair-loss guide too confidently attributed cases to temporary weight-loss shedding. Both now distinguish the product label from possible explanations, and avoid promises about when symptoms or hair growth will recover. We also replaced an unrelated reference that had been cited for a dermatology claim.

  3. Sleep, exercise and lean mass: stronger claims than the studies support

    We removed an unsupported sleep-improvement timeline and clarified that studies of sleep restriction or other medicines do not establish a semaglutide-specific result. The exercise guide no longer says exercise has no additional effect on weight. The lean-mass guide now distinguishes lean tissue from muscle and explains why pooled estimates cannot establish that different medicines have equivalent effects on muscle loss.

  4. Coffee and nausea: formulation and uncertainty matter

    We clarified that the wait-before-coffee instruction applies to oral semaglutide, rather than treating tablets and injections alike. We also removed a blanket reassurance about stronger caffeine sensations and an unsupported ranking of nausea remedies. The guides retain the need to discuss dose changes and persistent symptoms with the prescriber.

  5. Microdosing and organ-risk explanations corrected

    We removed statements that treated split or microdosed regimens as established extensions of standard titration. We also qualified explanations of bowel symptoms, gallbladder mechanisms and kidney reactions: a proposed mechanism or a volume-depletion warning does not establish the cause of every symptom or kidney event. Current product instructions and individual clinical assessment remain necessary.

  6. Cardiovascular evidence and medicine interactions updated

    We corrected statements that tirzepatide had no published cardiovascular outcomes trial, and distinguished Mounjaro’s current diabetes indication from Zepbound and the populations studied with Wegovy. We also removed broad reassurance about antidepressant absorption where direct combination studies were not available.

  7. Headache, reflux and heart-rate advice needed clearer limits

    We removed claims that most headaches have one preventable indirect cause, qualified explanations of burping and reflux, and corrected what a gastric-emptying study actually found. We also removed blanket reassurance about a faster heartbeat and clarified the label’s monitoring and reporting instructions.

  8. Injection instructions and oral tablet comparisons corrected

    We corrected the Wegovy injection guide to distinguish device types and removed incorrect branded-vial instructions. For the single-dose automatic pen, the second click does not mean the injection is complete; the yellow-bar instructions apply. We also updated oral tablet comparisons for current formulations and indications, and replaced generic vial-conversion directions with pharmacy verification steps.

  9. Dehydration: risk and fluid advice needed more qualification

    We removed statements that hydration would generally prevent kidney injury or that fluid loss explained every kidney reaction. The guide now states the limits of postmarketing reports and explains that heart failure, kidney disease and prescribed fluid or mineral restrictions require an individual plan.

  10. Older program reviews: pricing and commercial disclosures corrected

    Some older articles said we earned nothing from directing readers to programs, which conflicted with the affiliate links on this site. We corrected those statements and rechecked the programs’ current offerings and billing terms. The articles now separate membership from medication, introductory prices from renewals, and monthly installments from prepaid or four-week charges. Noom’s conflicting renewal prices remain identified rather than resolved by guesswork.

    Read the current review: Hims & Hers, Ro, Noom Med, Found, Calibrate

  11. Wegovy and program reviews: trial evidence is not customer-review evidence

    We removed broad summaries of customer experiences that lacked supporting review sources. The Wegovy guide now distinguishes clinical trial results and labeling from individual reports; the program articles focus on documented terms and practical questions. We also clarified that Wegovy pen directions must not be used to measure medication from a compounded vial.

  12. Medicare: a separate GLP-1 access program needed explaining

    Our cost guides described the ordinary Part D restriction on medicines used only for weight loss without explaining the separate Medicare GLP-1 Bridge. We added its eligibility requirements, covered products and cost, while keeping the distinction between that temporary program and ordinary drug-plan coverage.

  13. Wegovy: savings terms and a pill-price deadline were out of date

    We updated the manufacturer savings-card terms to the published minimum copay and monthly savings limit. We also removed a promised year-end pill-price change that the current manufacturer page does not state; the injection introductory offer has its own deadline. Pill and injection prices now identify their different supply periods.

  14. Bodybuilding Health+: $179 is the monthly price, not a first-month deal

    We had described $179 as a first-month price, with $279 as the regular rate. The company’s own savings figures are all calculated from $179, which makes it the standing month-to-month price for semaglutide. We corrected that, and updated the multi-month semaglutide and tirzepatide prices to what the company listed at the time.

    Read the current review: Bodybuilding Health+

  15. MEDGm: our disclosure said we were not paid, and that stopped being true

    The MEDGm review said we had no commercial relationship with the company. When MEDGm became a partner, that sentence became false, so we rewrote the disclosure the same day. Nothing else in the review changed.

    Read the current review: MEDGm

  16. LegitScript seals: we overstated what a seal check shows

    A few reviews called a provider’s LegitScript seal “independently verified” or “genuine” because its seal number worked. A working seal number only shows that the number was issued, not which website it was issued to. We removed the “verified” language. Plain statements that a company displays a LegitScript certification remain.

    Read the current review: WellMedr, HealthRX, Telos Rx

  17. He & She MD: the company does name its clinical provider

    We said He & She MD published no legal entity. Its FAQ does name the medical practice behind the service and a medical director; only the storefront’s own company name is unpublished. We corrected that, and added something more useful we had missed: the same FAQ says one of its two pharmacies is not licensed in ten states and cannot dispense sterile compounds, which matters for injectable GLP-1s.

    Read the current review: He & She MD

  18. Peter MD, Sprout and Eden do name their pharmacies

    We said these programs did not name the pharmacy that fills prescriptions. Each one does, in its own terms or about page, and the reviews now say which. We also removed a “503A pharmacy” label from Sprout, because Sprout does not state that itself.

    Read the current review: Peter MD, Sprout, Eden

  19. Oak: removed two figures that were discounts, not monthly prices

    We listed Oak “from $119 a month” for semaglutide and “from $185” for tirzepatide. On Oak’s own site those figures appear only next to a new-patient discount on a package, not as a monthly rate, and its other published starting prices disagree with each other. We removed both figures. The review now says Oak’s price is not clear without completing its intake.

    Read the current review: Oak

  20. FDA warning letters now shown on every page that lists a provider

    Some providers that have received an FDA warning letter did not have it mentioned on every page where they appear, and three (Curex, Eden and Hims) were not mentioned at all. Every list, comparison and review now shows the letter, whether or not the provider pays us.

    Read the current review: Curex, Eden, Hims, Strut, Sprout, Direct Meds, Zealthy

  21. Bodybuilding Health+: the $139 price was semaglutide, not tirzepatide

    We said tirzepatide dropped to $139 a month on a 12-month plan. That $139 was the semaglutide 12-month price; at the time, every multi-month tirzepatide plan actually cost more per month than paying monthly. We corrected the tirzepatide prices and confirmed the semaglutide ones were right.

    Read the current review: Bodybuilding Health+

  22. NovoCare: Wegovy's direct self-pay price was out of date

    Several articles and our Wegovy cost calculator used about $499 a month for Wegovy bought directly from Novo Nordisk’s NovoCare pharmacy. NovoCare then listed $199 a month for a new patient’s first two fills and $349 a month after that ($399 for the 7.2 mg pen), and $149 a month for the Wegovy pill. We corrected the articles, their tables and FAQs, and the calculator, and the calculator now dates each price separately instead of giving one date for all of them.

  23. Trimi and Direct Meds: both prices had changed

    The pages we had used for both companies no longer worked, and when we found their current sites, both prices had moved. Trimi was then $99 a month for semaglutide and $125 for tirzepatide, on annual plans only. Direct Meds was $249 a month for sublingual semaglutide, $297 for injections and $399 for tirzepatide. Both reviews were updated.

    Read the current review: Trimi, Direct Meds

  24. Cheapest list: sorted on the price you keep paying

    Our cheapest semaglutide list was sorted on each provider’s headline price, which is sometimes a first-month offer. It now sorts on the ongoing price where the company publishes one, and shows which price each provider was sorted on.

  25. How we make money: we described our commissions incorrectly

    Our disclosure page and several other pages said commissions never affected which providers we feature. That was wrong. We rewrote how Semawise makes money and every page that repeated the error to say so plainly.

  26. Two guides: citation and sourcing fixes

    We corrected the author names on the OASIS 4 trial citation in our oral Wegovy guide, and removed a dose figure from a comparison table in our Rybelsus guide because that article did not cite a source for it.